301 related articles for article (PubMed ID: 11292002)
1. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.
Ait-Daoud N; Johnson BA; Prihoda TJ; Hargita ID
Psychopharmacology (Berl); 2001 Feb; 154(1):23-7. PubMed ID: 11292002
[TBL] [Abstract][Full Text] [Related]
2. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.
Johnson BA; Ait-Daoud N; Prihoda TJ
Alcohol Clin Exp Res; 2000 May; 24(5):737-42. PubMed ID: 10832917
[TBL] [Abstract][Full Text] [Related]
3. Ondansetron reduces the craving of biologically predisposed alcoholics.
Johnson BA; Roache JD; Ait-Daoud N; Zanca NA; Velazquez M
Psychopharmacology (Berl); 2002 Apr; 160(4):408-13. PubMed ID: 11919668
[TBL] [Abstract][Full Text] [Related]
4. Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker.
Ait-Daoud N; Johnson BA; Javors M; Roache JD; Zanca NA
Alcohol Clin Exp Res; 2001 Jun; 25(6):847-9. PubMed ID: 11410720
[TBL] [Abstract][Full Text] [Related]
5. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals.
Johnson BA; Ait-Daoud N; Ma JZ; Wang Y
Alcohol Clin Exp Res; 2003 Nov; 27(11):1773-9. PubMed ID: 14634493
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
Johnson BA; Roache JD; Javors MA; DiClemente CC; Cloninger CR; Prihoda TJ; Bordnick PS; Ait-Daoud N; Hensler J
JAMA; 2000 Aug 23-30; 284(8):963-71. PubMed ID: 10944641
[TBL] [Abstract][Full Text] [Related]
7. Reductions in and relations between "craving" and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence.
Dawes MA; Johnson BA; Ma JZ; Ait-Daoud N; Thomas SE; Cornelius JR
Addict Behav; 2005 Oct; 30(9):1630-7. PubMed ID: 16084024
[TBL] [Abstract][Full Text] [Related]
8. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.
Chick J; Anton R; Checinski K; Croop R; Drummond DC; Farmer R; Labriola D; Marshall J; Moncrieff J; Morgan MY; Peters T; Ritson B
Alcohol Alcohol; 2000; 35(6):587-93. PubMed ID: 11093966
[TBL] [Abstract][Full Text] [Related]
9. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial.
Anton RF; Moak DH; Waid LR; Latham PK; Malcolm RJ; Dias JK
Am J Psychiatry; 1999 Nov; 156(11):1758-64. PubMed ID: 10553740
[TBL] [Abstract][Full Text] [Related]
10. Naltrexone treatment of adolescent alcoholics: an open-label pilot study.
Deas D; May MP; Randall C; Johnson N; Anton R
J Child Adolesc Psychopharmacol; 2005 Oct; 15(5):723-8. PubMed ID: 16262589
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.
O'Malley SS; Krishnan-Sarin S; Farren C; Sinha R; Kreek MJ
Psychopharmacology (Berl); 2002 Feb; 160(1):19-29. PubMed ID: 11862370
[TBL] [Abstract][Full Text] [Related]
12. Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people.
Myrick H; Anton RF; Li X; Henderson S; Randall PK; Voronin K
Arch Gen Psychiatry; 2008 Apr; 65(4):466-75. PubMed ID: 18391135
[TBL] [Abstract][Full Text] [Related]
13. Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.
Roache JD; Wang Y; Ait-Daoud N; Johnson BA
Alcohol Clin Exp Res; 2008 Aug; 32(8):1502-12. PubMed ID: 18565156
[TBL] [Abstract][Full Text] [Related]
14. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
[TBL] [Abstract][Full Text] [Related]
15. The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies.
Anton RF; Moak DH; Latham PK
Arch Gen Psychiatry; 1996 Mar; 53(3):225-31. PubMed ID: 8611059
[TBL] [Abstract][Full Text] [Related]
16. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
[TBL] [Abstract][Full Text] [Related]
17. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
[TBL] [Abstract][Full Text] [Related]
18. Real-time assessment of alcohol craving and naltrexone treatment responsiveness in a randomized clinical trial.
Miranda R; Treloar Padovano H; Gray JC; Wemm SE; Blanchard A
Addict Behav; 2018 Aug; 83():72-78. PubMed ID: 29395188
[TBL] [Abstract][Full Text] [Related]
19. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
20. Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient-Reported Outcomes in Adults with Alcohol Dependence.
O'Malley SS; Todtenkopf MS; Du Y; Ehrich E; Silverman BL
Alcohol Clin Exp Res; 2018 Oct; 42(10):2011-2021. PubMed ID: 30055046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
